Supplemental Figure Legends

Supplemental Figure 1. P4 activates the cSrc, AKT, ERK1/2, and p38 molecules in RASMCs. Treatment with P4 (50 nM) increased the levels of p-cSrc (a), p-AKT (b), p-ERK1/2 (c), and p-p38 (d) in RASMCs. Quantitative results of phosphorylated proteins were shown after adjusted with their own total protein level and expressed as fold induction of control. Values represent the mean±s.e.mean. (n=3). *P < 0.05 different from control group.

Supplemental Figure 2. Involvement of PR in the P4-induced activations of cSrc, AKT, ERK1/2 and p38. Pre-treatment of RASMCs with a PR specific antagonist, Org 31710 (1 μM), abolished the P4-induced increases of p-cSrc (a), p-AKT (b), p-ERK1/2 (c), and p-p38 (d). Con, control; P4, progesterone; ORG, Org 31710.

Supplemental Figures 3. The entire gel pictures of Figures 1 and 2 in the text. (a) Corresponding to Fig. 1a. (b) Corresponding to Fig. 1b. (c) Corresponding to Fig. 2a. (d) Corresponding to Fig. 2b. (e) Corresponding to Fig. 2c. (f) Corresponding to Fig. 2d.

Supplemental Figures 4. The entire gel pictures of Figures 3 and 4 in the text. (a) Corresponding to Fig. 3a. (b) Corresponding to Fig. 3b. (c) Corresponding to Fig. 3c. (d) Corresponding to Fig. 4a. (e) Corresponding to Fig. 4b. (f) Corresponding to Fig. 4c. (g) Corresponding to Fig. 4d. (h) Corresponding to Fig. 4e.

Supplemental Figures 5. The entire gel pictures of Figures 5 and 6 in the text. (a) Corresponding to Fig. 5a. (b) Corresponding to Fig. 5b. (c) Corresponding to Fig. 5c. (d) Corresponding to Fig. 5d. (e) Corresponding to Fig. 6a. (f) Corresponding to Fig. 6b. (g) Corresponding to Fig. 6c.
Supplemented Figure 2